Most Profitable NASDAQ Biotechnology Companies

Net Income
Net IncomeEfficiencyMarket RiskExp Return
1AZN AstraZeneca PLC ADR
6.9 B
(0.31)
 1.46 
(0.46)
2AMGN Amgen Inc
6.72 B
(0.11)
 1.57 
(0.17)
3GILD Gilead Sciences
5.61 B
 0.19 
 1.43 
 0.27 
4SNY Sanofi ADR
5.4 B
(0.20)
 1.20 
(0.24)
5GMAB Genmab AS
4.35 B
(0.30)
 1.48 
(0.44)
6ROIV Roivant Sciences
4.23 B
 0.00 
 1.58 
 0.00 
7REGN Regeneron Pharmaceuticals
3.95 B
(0.43)
 1.70 
(0.73)
8VRTX Vertex Pharmaceuticals
3.62 B
(0.05)
 1.73 
(0.09)
9BNTX BioNTech SE
1.19 B
 0.11 
 3.61 
 0.38 
10BIIB Biogen Inc
1.16 B
(0.31)
 1.30 
(0.40)
11RPRX Royalty Pharma Plc
1.13 B
(0.08)
 1.00 
(0.08)
12UTHR United Therapeutics
984.8 M
 0.06 
 1.73 
 0.10 
13INCY Incyte
597.6 M
 0.07 
 2.47 
 0.17 
14JAZZ Jazz Pharmaceuticals PLC
414.83 M
 0.08 
 2.05 
 0.17 
15ALKS Alkermes Plc
355.76 M
 0.01 
 2.31 
 0.01 
16MEDP Medpace Holdings
282.81 M
(0.06)
 2.98 
(0.17)
17HALO Halozyme Therapeutics
281.59 M
(0.12)
 3.69 
(0.42)
18NBIX Neurocrine Biosciences
249.7 M
(0.09)
 2.93 
(0.27)
19GLPG Galapagos NV ADR
211.7 M
(0.01)
 2.39 
(0.01)
20EXEL Exelixis
207.76 M
 0.21 
 2.36 
 0.49 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.